Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Clicks: 384
ID: 268642
2017
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #8 of 46 articles by views in gastroenterology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In phase 3 trials of patients with HCV infection, we did not establish that sofosbuvir-velpatasvir-voxilaprevir for 8 weeks was noninferior to sofosbuvir-velpatasvir for 12 weeks, but the 2 regimens had similar rates of SVR in patients with HCV genotype 3 and cirrhosis. Mild gastrointestinal adverse …
Reference Key
im2017gastroenterologyefficacy Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jacobson IM;Lawitz E;Gane EJ;Willems BE;Ruane PJ;Nahass RG;Borgia SM;Shafran SD;Workowski KA;Pearlman B;Hyland RH;Stamm LM;Svarovskaia E;Dvory-Sobol H;Zhu Y;Subramanian GM;Brainard DM;McHutchison JG;Bräu N;Berg T;Agarwal K;Bhandari BR;Davis M;Feld JJ;Dore GJ;Stedman CAM;Thompson AJ;Asselah T;Roberts SK;Foster GR;;
Journal gastroenterology
Year 2017
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/28390869
Keywords
hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine adult female male adolescent aged middle aged young adult 80 and over Clinical Trial Phase III Randomized Controlled Trial Multicenter Study drug therapy combination antiviral agents / administration & dosage antiviral agents / therapeutic use* antiviral agents / adverse effects ira m jacobson chronic / drug therapy* sofosbuvir / administration & dosage sustained virologic response sulfonamides / therapeutic use* sulfonamides / adverse effects pmid:28390869 doi:10.1053/j.gastro.2017.03.047 eric lawitz graham r foster carbamates / administration & dosage carbamates / adverse effects carbamates / therapeutic use* heterocyclic compounds 4 or more rings / administration & dosage 4 or more rings / adverse effects 4 or more rings / therapeutic use* macrocyclic compounds / administration & dosage macrocyclic compounds / adverse effects macrocyclic compounds / therapeutic use* sofosbuvir / adverse effects sofosbuvir / therapeutic use* sulfonamides / administration & dosage

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.